glp 1 with 3 receptors Understanding GLP-1 receptor agonists and their impact on drug discovery The GLP-1R as a model

The evaluating clinician determines which option is appropriate

8 Data from a phase 2 trial of 338 adults with obesity without diabetes suggests substantial weight loss benefit with retatrutide, with 26% of participants having a body weight reduction of 30% with the highest dose of retatrutide (12 mg SC once weekly)

they lack proper experimental studies and evidence

Outside of GLP and/or GIP receptor agonism, emerging novel strategies are largely preclinical or in Phase 1 studies

They also tracked how adverse event mentions fluctuated during key events, including the FDA approval of Wegovy for pediatric use in December 2022, Oprah Winfrey's public endorsement in December 2023, and the expansion of Medicare coverage for weight loss medications in March 2024